Citro Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 30-07-2024
- Paid Up Capital ₹ 0.10 M
as on 30-07-2024
- Company Age 8 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -26.52%
(FY 2023)
- Profit -61.76%
(FY 2023)
- Ebitda -111.13%
(FY 2023)
- Net Worth 14.32%
(FY 2023)
- Total Assets -1.20%
(FY 2023)
About Citro Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ashfaq Ahmed, Shaikh Ahmed, and Mukhtar Ahmed serve as directors at the Company.
- CIN/LLPIN
U24230KA2016PTC097166
- Company No.
097166
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Oct 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Citro Pharma Private Limited offer?
Citro Pharma Private Limited offers a wide range of products and services, including Cardiovascular Drugs & Medication, Kidney Drugs, Anti Cancer Medicines, Injectable Products, Pharmaceutical Injectables, Antibiotic Injection, Ceftriaxone Injection, Cyclophosphamide, Antifungal Injection, Tablet & Syrup, Itraconazole Capsule and Tablet.
Who are the key members and board of directors at Citro Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mukhtar Ahmed  | Director | 14-Oct-2016 | Current |
| Shaikh Ahmed | Director | 14-Oct-2016 | Current |
| Ashfaq Ahmed | Director | 14-Oct-2016 | Current |
Financial Performance of Citro Pharma.
Citro Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 26.52% decrease. The company also saw a substantial fall in profitability, with a 61.76% decrease in profit. The company's net worth Soared by an impressive increase of 14.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Citro Pharma?
In 2023, Citro Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
American Middle Eastern Medical Solutions Private LimitedActive 3 years 11 monthsAshfaq Ahmed is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Citro Pharma?
Unlock and access historical data on people associated with Citro Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Citro Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Citro Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
